Omeros (NASDAQ:OMER) Given Buy Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Omeros (NASDAQ:OMER) in a report published on Tuesday morning,Benzinga reports. They currently have a $36.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts also recently issued reports on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research report on Thursday, January 22nd. WBB Securities reiterated a “strong-buy” rating and issued a $45.00 target price on shares of Omeros in a research note on Wednesday, October 15th. Wall Street Zen lowered shares of Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Finally, HC Wainwright raised their target price on shares of Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Omeros has a consensus rating of “Moderate Buy” and a consensus price target of $40.33.

Omeros Stock Up 9.9%

Shares of NASDAQ:OMER opened at $12.67 on Tuesday. The firm has a market capitalization of $898.30 million, a price-to-earnings ratio of -6.27 and a beta of 2.38. The stock’s 50 day moving average is $11.81 and its 200-day moving average is $7.45. Omeros has a twelve month low of $2.95 and a twelve month high of $17.65.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.39. Equities research analysts anticipate that Omeros will post -3.09 earnings per share for the current fiscal year.

Insider Transactions at Omeros

In other Omeros news, CAO David J. Borges sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 12.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Omeros

A number of institutional investors have recently added to or reduced their stakes in OMER. Farther Finance Advisors LLC increased its stake in shares of Omeros by 16.5% during the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 1,004 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Omeros by 9.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 31,728 shares of the biopharmaceutical company’s stock worth $545,000 after purchasing an additional 2,631 shares during the last quarter. Harbour Investments Inc. boosted its holdings in shares of Omeros by 46.1% during the 2nd quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 4,251 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Omeros by 113.1% in the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 5,677 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Omeros by 7.1% in the 3rd quarter. Rhumbline Advisers now owns 105,873 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 7,048 shares during the last quarter. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.